COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  OutcomesOutcomes
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2 = 0.00; I​2 = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementAll studies89%0.11 [0.01-0.85]0/1578/12089% improvement2 fluvoxamine COVID-19 studiesc19fluvoxamine.com 7/25/21Tau​2 = 0.00; I​2 = 0.0%; Z = 2.12 (p = 0.017)Effect extraction pre-specifiedLower RiskIncreased Risk
4/20
Review Sukhatme et al., Front. Pharmacol., doi:10.3389/fphar.2021.652688 (Review) (Peer Reviewed) review Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Details   Review of mechanisms of action of fluvoxamine and other SSRIs that could be beneficial for COVID-19 treatment, including lower platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, reg..
3/6
Review Kirsch, S. (Review) (Preprint) review COVID FAQ
Details   COVID FAQ from the founder of the COVID-19 Early Treatment Fund [1], including an extensive analysis of the fluvoxamine trials and other supporting evidence.
2/1
Early Seftel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050 (Peer Reviewed) death/ICU, ↓83.9%, p=0.15 Prospective cohort of fluvoxamine for early treatment of COVID-19
Details   Prospective quasi-randomized (patient choice) study with 125 outpatients, 77 treated with fluvoxamine, showing lower death/ICU admission (0 of 77 vs. 2 of 48), lower hospitalization (0 of 77 vs. 6 of 48), and faster recovery with treatmen..
11/12
Early Lenze et al., JAMA, doi:10.1001/jama.2020.22760 (Peer Reviewed) progression, ↓92.7%, p=0.009 Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
Details   RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control).
8/17
Late Hoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01021-4 (Peer Reviewed) Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
Details   Retrospective 7,230 hospitalized COVID-19 patients in France, 345 receiving an antidepressant medication within 48 hours of admission. There was a significant association between antidepressant use and reduced risk of intubation or death ..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit